Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trialCharu Aggarwal, Nehal J. Lakhani, Dan P. Zandberg et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 140
Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3John D. Powderly, Bartosz Chmielowski, Gregory M. Coté et al.|Journal for ImmunoTherapy of Cancer|2015Cited by 101
Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of CancerLaird Bloom, Wei Cao, Bilian Li et al.|Antibodies|2016Cited by 94
IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcγRIIA and FcγRIIBCarol Cady, John C. Cambier, Maree S. Powell et al.|Immunology Letters|2009Cited by 87
Biomarkers and Surrogate Endpoints in Renal Transplantation: Present Status and Considerations for Clinical Trial DesignPeter A. Lachenbruch, Robert B. Colvin, Amy S. Rosenberg et al.|American Journal of Transplantation|2004Cited by 73